Sildenafil belongs to the phosphodiesterase type 5 (PDE5) inhibitor class alongside tadalafil, vardenafil and avanafil. All four drugs inhibit PDE5 and enhance nitric-oxide-related cGMP signaling, but they are separate active ingredients with different pharmacokinetic, molecular and product-label profiles. Sharing a mechanism therefore does not make their timing, food effects or duration-related characteristics interchangeable.
Some of the clearest differences can be seen in their concentration-time profiles. In fasting pharmacokinetic data, sildenafil and vardenafil both have median peak-concentration times of about 60 minutes, avanafil has a median Tmax of approximately 30 to 45 minutes, and tadalafil reaches its median peak later at about 2 hours. Tadalafil also has a substantially longer terminal half-life than the other three medicines.
This page provides a class-level orientation rather than reproducing every pairwise comparison. Use it to understand which dimensions actually distinguish PDE5 inhibitors, then continue to sildenafil vs tadalafil, sildenafil vs vardenafil or sildenafil vs avanafil when a specific two-drug comparison is needed.
PDE5 inhibitors are medicines defined by their ability to inhibit phosphodiesterase type 5, an enzyme responsible for degrading cyclic guanosine monophosphate, or cGMP. During sexual stimulation, nitric oxide signaling increases cGMP in the corpus cavernosum, and inhibition of PDE5 allows that signaling to persist longer.
Sildenafil, tadalafil, vardenafil and avanafil all use this broad mechanism in the erectile-dysfunction context. They do not directly replace the need for upstream physiological signaling, and class membership does not mean that they are the same molecule or have the same concentration-response relationship.
The most useful class comparison therefore starts with what is shared—the PDE5 target—and then separates the properties that belong to each individual active ingredient.
| Medicine | Drug Class | Primary Target | Same Active Ingredient as Sildenafil? |
|---|---|---|---|
| Sildenafil | PDE5 inhibitor | PDE5 | Yes |
| Tadalafil | PDE5 inhibitor | PDE5 | No |
| Vardenafil | PDE5 inhibitor | PDE5 | No |
| Avanafil | PDE5 inhibitor | PDE5 | No |
The most visible class-level differences appear when the concentration-time profiles are placed side by side. Under fasting conditions, sildenafil reaches its observed peak within approximately 30 to 120 minutes, with a median Tmax of about 60 minutes. Film-coated vardenafil has a similar reported range of approximately 30 minutes to 2 hours and the same median of about 60 minutes.
Avanafil has an earlier labeled median fasting Tmax of approximately 30 to 45 minutes. Tadalafil differs in the other direction: its maximum observed concentration is reached between approximately 30 minutes and 6 hours, with a median of about 2 hours in the ED tablet pharmacokinetic data.
These numbers are useful for describing absorption and peak timing, but they are not interchangeable with clinical onset. A drug can begin producing a pharmacodynamic response before its maximum measured plasma concentration is reached.
| PK Characteristic | Sildenafil | Tadalafil | Vardenafil | Avanafil |
|---|---|---|---|---|
| Fasting Tmax | 30–120 min; median about 60 min | 30 min–6 h; median about 2 h | 30 min–2 h; median about 60 min | Median about 30–45 min |
| Terminal half-life | About 4 h | About 17.5 h | About 4–5 h | About 5 h |
| Oral systemic PK | Yes | Yes | Yes | Yes |
| Same concentration-time profile? | — | No | No | No |
Timing comparisons become misleading when Tmax, labeled administration timing and clinical onset are treated as though they were the same measurement. Tmax is strictly pharmacokinetic: it identifies when the maximum observed plasma concentration occurs. Onset instead describes when an observable pharmacodynamic or clinical response begins.
Product labels add another timing concept by describing when a medicine may be administered relative to anticipated sexual activity. Sildenafil labeling generally centers administration around approximately one hour beforehand, while vardenafil film-coated tablets also use an approximately 60-minute framework. Avanafil labeling permits administration as early as approximately 15 minutes in specified dosing contexts.
Tadalafil has a different timing model because its as-needed labeling describes use before anticipated sexual activity and an erectile-response window extending much further after administration. It also has a once-daily ED regimen that is not tied to the timing of sexual activity in the same way. For sildenafil-specific timing interpretation, see sildenafil onset and sildenafil Tmax.
| Timing Concept | What It Actually Describes |
|---|---|
| Tmax | Time of maximum observed plasma concentration |
| Labeled administration timing | When a product label instructs or permits administration relative to anticipated activity |
| Clinical onset | Beginning of an observable pharmacodynamic response |
| Duration | Period over which a relevant response can persist |
Sildenafil, vardenafil and avanafil have terminal elimination half-lives within a broadly similar several-hour range. Current labels describe approximately 4 hours for sildenafil, approximately 4 to 5 hours for vardenafil and approximately 5 hours for avanafil.
Tadalafil is the major outlier in this comparison, with a mean terminal half-life of approximately 17.5 hours. Its longer concentration-decline profile is consistent with the substantially longer timing context described in tadalafil labeling, including evidence of improved erectile function compared with placebo up to 36 hours after an as-needed dose.
Half-life should still not be used as a mathematical synonym for effect duration. Drug concentrations, target interaction, physiological signaling and the threshold required for a clinical response all contribute to the relationship between plasma persistence and observed effect. For the distinction on the sildenafil side, see sildenafil half-life and sildenafil duration.
| Medicine | Approximate Terminal Half-Life | Interpretation |
|---|---|---|
| Sildenafil | About 4 hours | Several-hour systemic concentration-decline profile |
| Tadalafil | About 17.5 hours | Substantially longer concentration persistence |
| Vardenafil | About 4–5 hours | Broadly similar elimination timescale to sildenafil |
| Avanafil | About 5 hours | Broadly similar several-hour elimination timescale |
Food effects are another clear example of why drugs in the same class should not be assumed to behave identically. A high-fat meal slows sildenafil absorption: current labeling reports a mean Tmax delay of about 60 minutes and a mean Cmax reduction of approximately 29 percent.
Tadalafil differs because its labeled rate and extent of absorption are not meaningfully influenced by food. Film-coated vardenafil can also show a reduction in peak concentration with high-fat meals, with studies in its labeling reporting Cmax reductions ranging from approximately 18 to 50 percent. The food profile of vardenafil can additionally depend on formulation, which is why film-coated and orally disintegrating products should not automatically be treated identically.
Avanafil also shows slower absorption with a high-fat meal: the labeled study reports a mean Tmax delay of approximately 1.12 to 1.25 hours and a Cmax reduction of about 39 percent, while AUC changes only slightly. For deeper interpretation of the sildenafil findings, see sildenafil food effects.
| Medicine | High-Fat Meal Context |
|---|---|
| Sildenafil | Mean Tmax delayed about 60 min; mean Cmax reduced about 29% |
| Tadalafil | Rate and extent of absorption not meaningfully influenced by food |
| Vardenafil | Film-coated-tablet studies report Cmax reductions of about 18–50% |
| Avanafil | Mean Tmax delayed about 1.12–1.25 h; Cmax reduced about 39%; AUC changes only slightly |
CYP3A metabolism is important across all four medicines, creating a shared reason to pay attention to drugs that inhibit or induce this enzyme system. That common pathway does not mean that the contribution of individual enzymes, metabolite activity or the magnitude of an interaction will be identical for every PDE5 inhibitor.
Sildenafil is metabolized predominantly through CYP3A, with CYP2C9 acting as a minor pathway, and its major circulating N-desmethyl metabolite retains pharmacological activity. Tadalafil is predominantly metabolized by CYP3A4, but its major circulating metabolite is not expected to be pharmacologically active at observed concentrations.
Vardenafil is metabolized mainly by CYP3A4 with contributions from CYP3A5 and CYP2C isoforms, while its M1 metabolite retains some PDE5 activity. Avanafil is also cleared mainly through CYP3A4 with a minor CYP2C contribution and produces metabolites with differing degrees of PDE5 activity. For sildenafil-specific detail, see sildenafil metabolism and sildenafil and CYP3A4.
| Medicine | Major Metabolic Context | Active-Metabolite Context |
|---|---|---|
| Sildenafil | CYP3A major; CYP2C9 minor | Major N-desmethyl metabolite retains activity |
| Tadalafil | Predominantly CYP3A4 | Major circulating metabolite not expected to be pharmacologically active at observed levels |
| Vardenafil | CYP3A4 major; CYP3A5 and CYP2C contribute | M1 retains partial PDE5 activity |
| Avanafil | CYP3A4 major; CYP2C minor | M4 retains limited PDE5 activity; M16 is inactive against PDE5 |
PDE5 inhibitors are selective for PDE5, but their relative activity against other phosphodiesterase enzymes differs. These in-vitro selectivity patterns help explain why the molecules cannot be treated as pharmacologically identical simply because PDE5 is their shared primary target.
One useful example is PDE6, an enzyme involved in retinal phototransduction. Product labeling reports sildenafil as approximately 10-fold more potent against PDE5 than PDE6, vardenafil as more than 15-fold selective, avanafil as more than 100-fold selective and tadalafil as approximately 700-fold more potent against PDE5 than PDE6.
Those figures come from individual product-label in-vitro studies rather than a single standardized head-to-head experiment, so they should be treated as orientation values rather than a clinical ranking. Tadalafil also has its own distinctive interaction profile with PDE11 subtypes, reinforcing the point that selectivity patterns extend beyond one comparison enzyme.
| Medicine | Label-Reported PDE5 vs PDE6 Selectivity | Important Qualification |
|---|---|---|
| Sildenafil | Approximately 10-fold | In-vitro product-label value |
| Tadalafil | Approximately 700-fold | In-vitro product-label value |
| Vardenafil | Greater than 15-fold | In-vitro product-label value |
| Avanafil | Greater than 100-fold | In-vitro product-label value |
Pharmacological class is only one layer of medicine identity. Individual products can differ in dosage form, dosing framework, approved indication and brand or generic context even when their active ingredients belong to the same class.
In the U.S. ED context, sildenafil is widely represented by oral tablet products. Tadalafil has both as-needed and once-daily ED labeling and also appears in labeled BPH and combined ED/BPH contexts. Vardenafil has film-coated tablet and orally disintegrating tablet product contexts, while avanafil is represented by oral Stendra tablets.
Sildenafil itself also appears outside the narrow ED tablet comparison in other formulations and indication contexts. For those distinctions, see sildenafil formulations and sildenafil uses.
| Medicine | Selected Product / Label Distinction |
|---|---|
| Sildenafil | Oral ED tablets plus other sildenafil products and clinical contexts |
| Tadalafil | As-needed and once-daily ED frameworks; additional BPH-related labeling |
| Vardenafil | Film-coated and orally disintegrating tablet contexts |
| Avanafil | Oral tablet product represented by the Stendra brand context |
Because these medicines all inhibit PDE5 and can contribute to vasodilation, some major safety themes recur across the class. Organic nitrates are an important contraindication context, and guanylate-cyclase stimulators such as riociguat are also relevant because combining these mechanisms can produce excessive blood-pressure lowering.
However, class similarity should not be used as a substitute for checking the individual product label. CYP interactions, dose-adjustment instructions, cardiovascular precautions and guidance for specific populations differ among the individual active ingredients and products.
This class-level page does not reproduce four complete safety labels. For the sildenafil-specific framework, see sildenafil contraindications, sildenafil drug interactions, sildenafil and nitrates and sildenafil and riociguat.
| Safety Dimension | Class-Level Interpretation |
|---|---|
| Organic nitrates | Major contraindication theme for PDE5 inhibitors |
| Guanylate cyclase stimulators | Important contraindication theme |
| CYP3A modifiers | Relevant across the class, with drug-specific instructions |
| Individual labeling | Required for medicine-specific warnings and adjustments |
No single pharmacokinetic value captures the entire difference between sildenafil and other PDE5 inhibitors. Tmax answers when peak plasma concentration occurs, half-life describes concentration decline, food studies describe absorption under particular meal conditions and selectivity studies describe molecular interactions in vitro. Each measurement addresses a different part of drug behavior.
This distinction is especially important when apparently simple numbers point in different directions. Avanafil has an earlier median Tmax than sildenafil, while tadalafil has a much longer half-life and a longer labeled timing context. Vardenafil, meanwhile, is relatively close to sildenafil in median Tmax and terminal half-life but still differs in molecular selectivity, food effects and formulation.
The useful conclusion is therefore a profile rather than a ranking: the four medicines share PDE5 inhibition but express that class mechanism through different pharmacokinetic and product characteristics. The dedicated pairwise guides provide the next level of detail when one specific comparison matters.
| Comparison Question | Most Relevant Dimension |
|---|---|
| Do all four medicines share a primary target? | Yes — PDE5 inhibition |
| Which reaches peak concentration earliest on average? | Compare fasting Tmax, while keeping Tmax separate from clinical onset |
| Which has the most distinct concentration-persistence profile? | Compare terminal half-life |
| Why do meals matter differently? | Compare medicine-specific food-effect pharmacokinetics |
| Why can interaction profiles differ? | Compare CYP pathways, metabolites and individual labeling |
| Why can off-target pharmacology differ? | Compare PDE selectivity profiles |
| Where should detailed two-drug questions go? | Dedicated sildenafil-vs-drug comparison pages |
Sildenafil shares PDE5 inhibition with tadalafil, vardenafil and avanafil, but the four drugs differ in peak-concentration timing, half-life, food effects, metabolism, PDE selectivity and product-label characteristics.
Yes. All four are PDE5 inhibitors, but they are separate active ingredients rather than different names for the same medicine.
Current U.S. labeling reports a median fasting Tmax of about 30 to 45 minutes for avanafil, about 60 minutes for sildenafil and vardenafil, and about 2 hours for tadalafil. Tmax describes peak plasma timing and is not the same as clinical onset.
Tadalafil has a substantially longer mean terminal half-life at about 17.5 hours. Sildenafil is about 4 hours, vardenafil about 4 to 5 hours and avanafil about 5 hours in current labeling.
No. Tmax identifies when maximum observed plasma concentration occurs. Clinical onset is a pharmacodynamic concept and does not have to occur at the same time as Cmax.
Yes. High-fat meals slow sildenafil absorption and can reduce vardenafil and avanafil peak concentrations, while tadalafil labeling states that its rate and extent of absorption are not influenced by food.
One major pharmacokinetic difference is tadalafil's approximately 17.5-hour terminal half-life, which is substantially longer than the several-hour half-lives reported for sildenafil, vardenafil and avanafil. Clinical timing still should not be inferred from half-life alone.
No. Although PDE5 is their shared primary target, their relative activity against other phosphodiesterases differs. Product labels report different in-vitro selectivity profiles for sildenafil, tadalafil, vardenafil and avanafil.
CYP3A metabolism is important across these medicines, but the exact pathways, metabolites and prescribing instructions differ by drug. Individual product labeling is therefore needed for interaction interpretation.
Current U.S. tadalafil labeling includes both as-needed and once-daily erectile-dysfunction regimens. The other medicines in this class comparison have different product and administration frameworks.
Dedicated pages provide deeper comparisons for sildenafil versus tadalafil, sildenafil versus vardenafil and sildenafil versus avanafil, including their pharmacokinetic, timing and product-specific differences.